Drug Profile
Research programme: protein arginine methyltransferase 5 inhibitors - Cancer Therapeutics/Merck
Alternative Names: PRMT5 program; protein arginine methyltransferase 5 programLatest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Cancer Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein methyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Haematological disorders
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for preclinical development in Cancer in Australia
- 28 Feb 2020 No recent reports of development identified for preclinical development in Haematological-disorders in Australia